CLEU20136 / EA9181 / O'Dwyer
Basic Study Information
Purpose:Location: University of Rochester
This phase III trial compares the effect of usual treatment of chemotherapy and steroids
and a tyrosine kinase inhibitor (TKI) to the same treatment plus blinatumomab. Blinatumomab
is a Bi-specific T-Cell Engager ('BiTE') that may interfere with the ability of cancer
cells to grow and spread. The information gained from this study may help researchers
determine if combination therapy with steroids, TKIs, and blinatumomab work better
than the standard of care.
Lead Researcher (Principal Investigator)
Study Contact InformationStudy Coordinator: Tina Bowdish
Phone: +1 585-275-9475
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search